![]() |
Name |
Tajixanthone hydrate
|
Molecular Formula | C25H30O8 | |
IUPAC Name* |
(1R,2S)-8-[(2S)-2,3-dihydroxy-3-methylbutyl]-1,11-dihydroxy-5-methyl-2-prop-1-en-2-yl-2,3-dihydro-1H-pyrano[3,2-a]xanthen-12-one;hydrate
|
|
SMILES |
CC1=CC2=C(C3=C1OC[C@@H]([C@H]3O)C(=C)C)C(=O)C4=C(C=CC(=C4O2)C[C@@H](C(C)(C)O)O)O.O
|
|
InChI |
InChI=1S/C25H28O7.H2O/c1-11(2)14-10-31-23-12(3)8-16-19(20(23)21(14)28)22(29)18-15(26)7-6-13(24(18)32-16)9-17(27)25(4,5)30;/h6-8,14,17,21,26-28,30H,1,9-10H2,2-5H3;1H2/t14-,17+,21-;/m1./s1
|
|
InChIKey |
OWNCSJANCRIYNY-OKLLSCIYSA-N
|
|
Synonyms |
Tajixanthone hydrate; CHEMBL456494
|
|
CAS | NA | |
PubChem CID | 44581699 | |
ChEMBL ID | CHEMBL456494 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 458.5 | ALogp: | 2.4 |
HBD: | 5 | HBA: | 8 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 117.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 33 | QED Weighted: | 0.346 |
Caco-2 Permeability: | -5.02 | MDCK Permeability: | 0.00000905 |
Pgp-inhibitor: | 0.035 | Pgp-substrate: | 0.955 |
Human Intestinal Absorption (HIA): | 0.112 | 20% Bioavailability (F20%): | 0.007 |
30% Bioavailability (F30%): | 0.005 |
Blood-Brain-Barrier Penetration (BBB): | 0.044 | Plasma Protein Binding (PPB): | 86.88% |
Volume Distribution (VD): | 1.004 | Fu: | 9.60% |
CYP1A2-inhibitor: | 0.333 | CYP1A2-substrate: | 0.696 |
CYP2C19-inhibitor: | 0.033 | CYP2C19-substrate: | 0.186 |
CYP2C9-inhibitor: | 0.302 | CYP2C9-substrate: | 0.766 |
CYP2D6-inhibitor: | 0.132 | CYP2D6-substrate: | 0.199 |
CYP3A4-inhibitor: | 0.144 | CYP3A4-substrate: | 0.18 |
Clearance (CL): | 3.052 | Half-life (T1/2): | 0.156 |
hERG Blockers: | 0.013 | Human Hepatotoxicity (H-HT): | 0.557 |
Drug-inuced Liver Injury (DILI): | 0.855 | AMES Toxicity: | 0.672 |
Rat Oral Acute Toxicity: | 0.91 | Maximum Recommended Daily Dose: | 0.953 |
Skin Sensitization: | 0.269 | Carcinogencity: | 0.826 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.022 |
Respiratory Toxicity: | 0.188 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002697 | ![]() |
0.853 | D0K8KX | ![]() |
0.267 | ||
ENC002623 | ![]() |
0.781 | D04AIT | ![]() |
0.250 | ||
ENC002341 | ![]() |
0.724 | D0F7CS | ![]() |
0.243 | ||
ENC004145 | ![]() |
0.642 | D0Q0PR | ![]() |
0.241 | ||
ENC004314 | ![]() |
0.634 | D0O1UZ | ![]() |
0.240 | ||
ENC002544 | ![]() |
0.630 | D06GCK | ![]() |
0.238 | ||
ENC002916 | ![]() |
0.610 | D0O6KE | ![]() |
0.234 | ||
ENC006093 | ![]() |
0.610 | D0K5CB | ![]() |
0.234 | ||
ENC004537 | ![]() |
0.555 | D02ZJI | ![]() |
0.234 | ||
ENC004538 | ![]() |
0.555 | D04UTT | ![]() |
0.231 |